Applied nature for better science – LenioBio is disrupting the way proteins are made with our proprietary cell-free protein production platform, ALiCE®. ALiCE® is fast, versatile, mobile, and rapidly scalable – an ideal PPP: a pandemic preparedness platform – and attributable to a broad range of other applications. LenioBio holds an exclusive license from Dow/DuPont to develop and market the platform. Our ALiCE® expression kit and protein services generate revenues and open doors for strategic partnerships. LenioBio focuses now on scaling the technology to industrial scale. We received Seed funding and a Horizon 2020 grant in 2019.
Brought to you by
